Comparing the current results to its competitors, Gritstone Bio Inc reported Revenue decrease in the 2 quarter 2024 year on year by -52.89 %, faster than the overall decrease of Gritstone Bio Inc 's competitors by -11.7 %, recorded in the same quarter.
June 30, 2024
In an exclusive report by CSIMarket.com , we delve into the recent developments surrounding Gritstone Bio, Inc. and its ongoing securities class action lawsuit. Trusted and leading law firm, Rosen, highlights the significance of securing legal counsel before the approaching deadline. The case encompasses the period from March 9, 2023, to February 29, 2024, and investors must pay heed to the August 6, 2024, lead plaintiff deadline.Gritstone Bio, Inc., a prominent player in the biotechnology industry listed on NASDAQ under GRTS, is facing legal repercussions following allegations of potential securities law violations during the specified Class Period. Investors who purchased Gritstone s securities within thi...
April 1, 2024
Gritstone bio has announced positive preliminary results from the Phase 2 portion of its ongoing Phase 2/3 study of the cancer vaccine, GRANITE. The study concentrates on front-line metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC). The early data points to favorable progression-free survival (PFS) for patients treated with GRANITE. In the overall population, the hazard ratio was 0.82 (95% CI, 0.34-1.67; 62% censored). Within a high-risk group, the hazard ratio was even lower at 0.52 (95% CI, 0.15-1.38; 44% censored), signifying a relative risk reduction of 48% in progression or death. More than 90% of these high-risk patients presented liver metastases, indicating that this population has more ma...
February 12, 2024
EMERYVILLE, Calif., Feb. 12, 2024 - Gritstone bio, Inc. (Nasdaq: GRTS), a pioneering biotechnology company focused on developing the world s most powerful vaccines, has shared an important update on its comparative Phase 2b COVID-19 clinical trial. The company is now preparing to launch the much-anticipated trial in the Fall of 2024, rather than the previously scheduled 1Q24. This delay is necessary to incorporate fully Good Manufacturing Practice (GMP)-grade raw materials in the vaccine formulation, enabling enhanced regulatory compliance and optimizing the trial s potential.The decision to delay the Phase 2b trial stems from Gritstone Bio s commitment to ensuring the highest quality and efficacy of its nex...
Fate Therapeutics Inc's business model revolves around the development and commercialization of innovative cell-based therapies to treat various diseases.
Iovance Biotherapeutics Inc operates on a business model centered around developing and commercializing novel cancer immunotherapy treatments. The company focuses on utilizing its proprietary Tumor Infiltrating Lymphocyte (TIL) therapy, which involves collecting and expanding a patient's own immune cells to target and kill cancer cells. Iovance primarily seeks to advance its TIL therapy candidates through clinical trials and collaborations while aiming to provide effective and personalized treatment options for cancer patients.
Molecular Partners Ag is a biotechnology company that operates on an innovative business model focused on the development of therapeutic drugs. The company utilizes its proprietary DARPin technology platform to create a pipeline of potential treatments for various diseases. Molecular Partners Ag primarily collaborates with strategic partners, including pharmaceutical companies, to advance its drug candidates through preclinical and clinical development stages.
Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.
Sources:
Gritstone Bio Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Gritstone Bio Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
